Vir Biotechnology and Biogen are teaming up for the development and clinical manufacturing of human monoclonal antibodies for the potential treatment of Covid-19.
Due the to the urgency of the situation, the companies have already started work while a Clinical Development and Manufacturing Agreement is being negotiated.
Subject to the completion of a definitive agreement, Biogen would continue cell line development, process development, and clinical manufacturing activities in order to advance the development of Vir’s proprietary antibodies.
“These exceptional circumstances presented by the threat of Covid-19 require that we work with great urgency in the interest of the public good,” said George Scangos, CEO of Vir.
Vir has identified several monoclonal antibodies that bind to SARS-CoV-2, which were isolated from individuals who had survived a SARS infection.
The company is conducting research to determine if its antibodies, or additional antibodies that it may be able to identify, can be effective as treatment and/or prophylaxis against SARS-CoV-2.